What is the recommended treatment plan for a patient with an ACR (American College of Rheumatology) score of 23.8?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clarification Needed: ACR 23.8 Does Not Represent a Standard Clinical Measure

The value "ACR 23.8" does not correspond to any recognized American College of Rheumatology scoring system or clinical measurement used in rheumatology practice. This appears to be either a misunderstanding or miscommunication of a clinical value.

Possible Interpretations and Next Steps

If This Refers to ACR Response Criteria

  • ACR response criteria (ACR20, ACR50, ACR70) are categorical endpoints, not continuous numerical scores 1
  • These represent 20%, 50%, or 70% improvement in specific disease parameters in rheumatoid arthritis clinical trials 2, 3
  • They are used to assess treatment response, not to guide initial treatment decisions 1

If This Refers to Disease Activity Scores

Common disease activity measures in rheumatoid arthritis include:

  • DAS28 (Disease Activity Score-28): Ranges from 0-10, with scores >5.1 indicating high disease activity 4, 5
  • CDAI (Clinical Disease Activity Index): Ranges from 0-76, with scores >22 indicating high disease activity 6
  • RAPID3 (Routine Assessment of Patient Index Data 3): Ranges from 0-10, with scores >6 indicating moderate-high disease activity 6

If This Refers to Laboratory Values

  • Anti-CCP (anti-cyclic citrullinated peptide) antibodies: Measured in units/mL, with values >20 typically considered positive 7
  • Rheumatoid factor: Measured in IU/mL, with values >20 IU/mL considered positive 1, 3
  • CRP (C-reactive protein): Measured in mg/dL or mg/L 1, 2

Required Information for Treatment Recommendations

To provide appropriate treatment guidance, the following information is essential:

  • Validated disease activity score (DAS28, CDAI, SDAI, or RAPID3) 6, 4
  • Number of tender and swollen joints 1, 2
  • Patient and physician global assessments 1, 2
  • Inflammatory markers (ESR, CRP) 1, 7
  • Functional status (HAQ-DI score) 1, 2
  • Disease duration (early vs. established disease) 1, 5
  • Prior treatment history 1

Please clarify what "ACR 23.8" represents or provide standard disease activity measurements to receive appropriate treatment recommendations.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment Guidelines in Rheumatoid Arthritis.

Rheumatic diseases clinics of North America, 2022

Guideline

Golimumab Medical Necessity Assessment in Rheumatoid Arthritis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.